Horizon Therapeutics (original) (raw)
Horizon Therapeutics Public Limited Company (anciennement Horizon Pharma) est une entreprise pharmaceutique ayant ses principales activités aux États-Unis mais dont le siège social est en Irlande. Ses principaux produits sont liés au domaine de la douleur, de l'inflammation et de l'arthrite.
| Property | Value |
|---|---|
| dbo:abstract | Horizon Therapeutics Public Ltd Co is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019, shareholders of the company approved the change of the company's name to Horizon Therapeutics plc. Horizon's drug portfolio is focused on treatments for thyroid eye disease (TED), gout, rare diseases, and inflammatory diseases. Horizon's portfolio includes Tepezza (teprotumumab), Krystexxa (pegloticase), Actimmune (interferon gamma), Duexis (ibuprofen + famotidine), Pennsaid (diclofenac, 2% topical), Rayos/Lodotra (prednisone), Vimovo (naproxen/esomeprazole magnesium), Buphenyl (sodium phenylbutyrate), Procysbi (cysteamine bitartrate), and Ravicti (glycerol phenylbutyrate). In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). (en) Horizon Therapeutics Public Limited Company (anciennement Horizon Pharma) est une entreprise pharmaceutique ayant ses principales activités aux États-Unis mais dont le siège social est en Irlande. Ses principaux produits sont liés au domaine de la douleur, de l'inflammation et de l'arthrite. (fr) Horizon Therapeutics — международная фармацевтическая компания. Номинальная штаб-квартира расположена в Дублине (Ирландия), фактический центр операций в Чикаго (США). Специализируется на препаратах для лечения редких заболеваний. (ru) |
| dbo:foundingYear | 2005-01-01 (xsd:gYear) |
| dbo:headquarter | dbr:Dublin dbr:Lake_Forest,_Illinois |
| dbo:industry | dbr:Pharmaceutical |
| dbo:keyPerson | dbr:CEO |
| dbo:netIncome | 2.64E8 |
| dbo:numberOfEmployees | 1800 (xsd:nonNegativeInteger) |
| dbo:revenue | 3.22E9 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Horizon_Therapeutics_logo.svg?width=300 |
| dbo:type | dbr:Public_limited_company |
| dbo:wikiPageExternalLink | http://www.horizontherapeutics.com/ |
| dbo:wikiPageID | 42291505 (xsd:integer) |
| dbo:wikiPageLength | 12061 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1079178351 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:American_Gastroenterological_Association dbr:Prednisone dbr:Public_limited_company dbr:Rockville,_Maryland dbc:Pharmaceutical_companies_established_in_2005 dbr:Pegloticase dbr:Pharmaceutical dbr:Inflammation dbr:Pennsaid dbr:Quinsair dbc:Companies_listed_on_the_Nasdaq dbr:Corporation_tax_in_the_Republic_of_Ireland dbr:Rare_disease dbr:Glycerol_phenylbutyrate dbr:Gout dbr:Graves'_ophthalmopathy dbr:Procysbi dbr:Pharmaceutical_Research_and_Manufacturers_of_America dbr:Thyroid_eye_disease dbr:CEO dbc:Manufacturing_companies_based_in_Dublin_(city) dbc:Pharmaceutical_companies_of_Ireland dbr:Cysteamine dbr:Dublin dbr:Esomeprazole dbr:Osteoarthritis dbr:Ireland_as_a_tax_haven dbr:Teprotumumab dbc:Tax_inversions dbr:Lake_Forest,_Illinois dbr:Duexis dbr:Sodium_phenylbutyrate dbr:Interferon_gamma dbr:Naproxen dbr:Wall_Street_Journal dbr:Russell_1000 dbr:Raptor_Pharmaceutical |
| dbp:hqLocation | * Dublin, Ireland * Lake Forest , Illinois, USA (en) |
| dbp:industry | dbr:Pharmaceutical |
| dbp:isin | IE00BQPVQZ61 (en) |
| dbp:keyPeople | Andy Pasternak (en) Jeffrey W. Sherman, M.D. (en) Paul W. Hoelscher (en) Timothy P. Walbert (en) |
| dbp:logo | File:Horizon Therapeutics logo.svg (en) |
| dbp:name | Horizon Therapeutics plc (en) |
| dbp:netIncome | 2.64E8 |
| dbp:numEmployees | 1800 (xsd:integer) |
| dbp:predecessor | Horizon Pharma plc (en) |
| dbp:revenue | (en) 3.22E9 |
| dbp:type | dbr:Public_limited_company |
| dbp:wikiPageUsesTemplate | dbt:Authority_control dbt:Decrease dbt:Increase dbt:Infobox_company dbt:Reflist dbt:Short_description dbt:Start_date_and_age dbt:URL dbt:Ubl dbt:Pharmaceutical_companies_of_the_United_States |
| dcterms:subject | dbc:Pharmaceutical_companies_established_in_2005 dbc:Companies_listed_on_the_Nasdaq dbc:Manufacturing_companies_based_in_Dublin_(city) dbc:Pharmaceutical_companies_of_Ireland dbc:Tax_inversions |
| rdf:type | owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment | Horizon Therapeutics Public Limited Company (anciennement Horizon Pharma) est une entreprise pharmaceutique ayant ses principales activités aux États-Unis mais dont le siège social est en Irlande. Ses principaux produits sont liés au domaine de la douleur, de l'inflammation et de l'arthrite. (fr) Horizon Therapeutics — международная фармацевтическая компания. Номинальная штаб-квартира расположена в Дублине (Ирландия), фактический центр операций в Чикаго (США). Специализируется на препаратах для лечения редких заболеваний. (ru) Horizon Therapeutics Public Ltd Co is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019, shareholders of the company approved the change of the company's name to Horizon Therapeutics plc. (en) |
| rdfs:label | Horizon Therapeutics (fr) Horizon Therapeutics (en) Horizon Therapeutics (ru) |
| owl:sameAs | wikidata:Horizon Therapeutics dbpedia-fa:Horizon Therapeutics dbpedia-fr:Horizon Therapeutics dbpedia-ru:Horizon Therapeutics https://global.dbpedia.org/id/eGNC |
| prov:wasDerivedFrom | wikipedia-en:Horizon_Therapeutics?oldid=1079178351&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Horizon_Therapeutics_logo.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Horizon_Therapeutics |
| foaf:name | Horizon Therapeutics plc (en) |
| is dbo:wikiPageRedirects of | dbr:Horizon_Pharma dbr:Horizon_Pharma_Inc. dbr:Horizon_Pharma_plc |
| is dbo:wikiPageWikiLink of | dbr:List_of_companies_of_Ireland dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:Brand_Institute dbr:Innovative_Medicines_Canada dbr:List_of_largest_biomedical_companies_by_market_capitalization dbr:List_of_largest_companies_in_Ireland dbr:List_of_pharmaceutical_companies dbr:National_Organization_for_Rare_Disorders dbr:Genmab dbr:Horizon_Pharma dbr:Horizon_Pharma_Inc. dbr:Irish_Open_(golf) dbr:Lake_Cook_Road_station dbr:Lake_Forest,_Illinois dbr:Reagan-Udall_Foundation dbr:Russell_1000_Index dbr:Horizon_Pharma_plc |
| is foaf:primaryTopic of | wikipedia-en:Horizon_Therapeutics |
